Outcomes of Percutaneous Coronary Intervention in Hospitalized Patients with Acute Coronary Syndrome and Heart Failure: Insights from the CCC-ACS Registry Observational Study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Outcomes of Percutaneous Coronary Intervention in Hospitalized Patients with Acute Coronary Syndrome and Heart Failure: Insights from the CCC-ACS Registry Observational Study

  • By

  • Chu Fan

  • Hangyu Yan

  • Kehang Lei

  • Dan Li

  • Shutong Dong

  • Yue Zhang

  • Cecily Patricia Callister

  • Yutong Cheng

  • Zhao Li

  • Zhizhong Li

  • Haiyan Qian

  • Ji Huang

  • December 30, 2025

Share

  • 1

    Acute coronary syndrome patients with heart failure are classified as extremely high-risk and require urgent evaluation and treatment.

  • 2

    Percutaneous coronary intervention is the primary therapeutic strategy for coronary revascularization in acute coronary syndrome.

  • 3

    The CCC-ACS Project is a nationwide registry in China focusing on improving care for acute coronary syndrome patients.

  • 4

    The study analyzed 4,694 hospitalized ACS patients with heart failure to evaluate the impact of PCI on their outcomes.

  • 5

    Primary outcomes included all-cause death and major adverse cardiovascular events during hospitalization for the study population.

Original Source(s)

Outcomes of Percutaneous Coronary Intervention in Hospitalized Patients with Acute Coronary Syndrome and Heart Failure: Insights from the CCC-ACS Registry Observational Study

  • by Chu Fan, Hangyu Yan, Kehang Lei, Dan Li, Shutong Dong, Yue Zhang, Cecily Patricia Callister, Yutong Cheng, Zhao Li, Zhizhong Li, Haiyan Qian, Ji Huang

  • December 30, 2025

Related Content

Mortality score may refine heart allocation

A laboratory- and device-based model outperformed the current 6-status system in predicting short-term mortality among heart transplant candidates.

Circulating Dipeptidyl Peptidase 3 levels, an Antagonist of Angiotensin-(1–7), in Acute Heart Failure: Insights from the PUSH-AHF trial

Sodium Thiosulfate for Refractory Metabolic Alkalosis From Diuretic Therapy: A Case Series of Six Patients

  • September 1, 2026